Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma

Mounting evidence has found that tumor microenvironment (TME) plays an important role in the tumor progression of lung adenocarcinoma (LUAD). However, the roles of tumor microenvironment-related genes in immunotherapy and clinical outcomes remain unclear. In this study, 6 TME-related genes (PLK1, LD...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-08, Vol.13 (1), p.13568-13568, Article 13568
Main Authors: Li, Chunhong, Yuan, Yixiao, Jiang, Xiulin, Wang, Qiang
Format: Article
Language:English
Subjects:
631/114
631/67
692/53
Adenocarcinoma
Biomarkers
Cancer therapies
Clinical outcomes
Extracellular matrix
Fibroblasts
Furin
Gene expression
Genomics
Humanities and Social Sciences
Immunoregulation
Immunotherapy
Lung cancer
Lymphocytes T
Medical prognosis
Metastases
multidisciplinary
Mutation
Polo-like kinase 1
Science
Science (multidisciplinary)
Tumor microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mounting evidence has found that tumor microenvironment (TME) plays an important role in the tumor progression of lung adenocarcinoma (LUAD). However, the roles of tumor microenvironment-related genes in immunotherapy and clinical outcomes remain unclear. In this study, 6 TME-related genes (PLK1, LDHA, FURIN, FSCN1, RAB27B, and MS4A1) were identified to construct the prognostic model. The established risk scores were able to predict outcomes at 1, 3, and 5 years with greater accuracy than previously known models. Moreover, the risk score was closely associated with immune cell infiltration and the immunoregulatory genes including T cell exhaustion markers. In conclusion, the TME risk score can function as an independent prognostic biomarker and a predictor for evaluating immunotherapy response in LUAD patients, which provides recommendations for improving patients’ response to immunotherapy and promoting personalized tumor immunotherapy in the future.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-40980-2